Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avineuro Pharmaceuticals, a discoverer and developer of small molecules for unmet medical needs in neurology and psychiatry, has completed the preclinical studies of AVN-101, a potent small molecule for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
These studies have demonstrated that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, the company plans to advance AVN-101 into clinical trials in the first quarter of 2009.